Determination of a reference value for NG, NG- dimethyl-L-arginine in 500 subjects

European Journal of Clinical Investigation

Volumn 35, Issue 10, 2005, Pages 622-626

  Schulze, Friedrich ^a   Maas, R ^a   Freese, R ^b   Schwedhelm, E ^a   Silberhorn, E ^a   Boger R H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MDS Pharma Services   (Germany)

Author keywords

ADMA; Endothelium; Inhibitor; Menopause; NO synthase; Reference value

Indexed keywords

N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING;

ADULT; AGED; AGING; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEX CHARACTERISTICS;

EID: 26044460259     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01561.x     Document Type: Article

References (32)

1. Clarke S. Protein methylation. Curr Opin Cell Biol 1993;5:977-83.
2. McBride AE, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell 2001;106:5-8.
3. Boisvert FM, Cote J, Boulanger MC, Richard S. A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics 2003;2:1319-30.
4. Wada K, Inoue K, Hagiwara M. Identification of methylated proteins by protein arginine N-methyltransferase 1, PRMT1, with a new expression cloning strategy. Biochim Biophys Acta 2002;1591:1-10.
5. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
6. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455-9.
7. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-7.
8. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993;7:193-4.
9. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996;119:1533-40.
10. Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated 1-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary 1-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996;219:598-603.
11. Causse E, Siri N, Arnal JF, Bayle C, Malatray P, Valdiguie P et al. Determination of asymmetrical dimethylarginine by capillary electrophoresis- laser-induced fluorescence. J Chromatogr B Biomed Sci Appl 2000;741:777-83.
12. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005;51:1268-71.
13. G-[2H6] dimethylarginine as internal standard. J Chromatogr B Anal Technol Biomed Life Sci 2004;809:59-65.
14. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004;42:1377-83.
15. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997;15:901-9.
16. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction; its role in hypercholesterolaemia. Circulation 1998;98:1842-7.
17. Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst (e) inaemia in humans. Clin Sci (Lond) 2001;100:161-7.
18. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996;11:2449-52.
19. Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino L et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 2001;358:2113-7.
20. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003;24:1912-9.
21. Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values (EPTRV) and International Committee for Standardization in Haematology (ICSH) Standing Committee on Reference Values. Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. Clin Chim Acta 1987;170:S13-S32.
22. Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser S, Jameson JL, eds. Harrison's Principles of Internal Medicine. New York, USA: McGraw-Hill; 2005.
23. Schildkraut JM, Cooper GS, Halabi S, Calingaert B, Hartge P, Whittemore AS. Age at natural menopause and the risk of epithelial ovarian cancer. Obstet Gynecol 2001;98:85-90.
24. Teerlink T, Neele SJ, de Jong S, Netelenbos JC, Stehouwer CD. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) 2003;105:67-71.
25. Post MS, Verhoeven MO, van der Mooren MJ, Kenemans P, Stehouwer CD, Teerlink T. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 2003;88:4221-6.
26. Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 2003;108:1575-80.
27. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
28. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
29. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 2004;53:1574-9.
30. Krzyzanowska K, Mittermayer F, Kopp HP, Wolzt M, Schernthaner G. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab 2004;89:6277-81.
31. Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G, Wagner OF et al. Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes. Diabetologia 2002;45:1372-8.
32. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Chayama K, Oshima T. Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals and patients with essential hypertension. Am J Hypertens 2001;14:1038-45.